Cargando…

Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa

BACKGROUND: Updated World Health Organization (WHO) treatment guidelines prioritize all-oral drug-resistant tuberculosis (DR-TB) regimens. Several poorly tolerated drugs, such as amikacin and para-aminosalicylic acid (PAS), remain treatment options for DR-TB in WHO-recommended longer regimens as Gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietersen, Elize, Anderson, Kim, Cox, Helen, Dheda, Keertan, Bian, Aihua, Shepherd, Bryan E., Sterling, Timothy R., Warren, Robin M., van der Heijden, Yuri F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925007/ https://www.ncbi.nlm.nih.gov/pubmed/36780443 http://dx.doi.org/10.1371/journal.pone.0281097

Ejemplares similares

High mortality among patients hospitalized for drug‐resistant tuberculosis with acquired second‐line drug resistance and high HIV prevalence
por: Anderson, Kim, et al.
Publicado: (2022)

What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?
por: Pooran, Anil, et al.
Publicado: (2013)

High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
por: Pietersen, Elize, et al.
Publicado: (2015)

Comparison of treatment outcome definitions in drug-resistant tuberculosis patients with high incidence of acquired second-line drug resistance
por: Anderson, K, et al.
Publicado: (2022)

Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa
por: Shean, Karen, et al.
Publicado: (2013)

Correction: Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa
por: Shean, Karen, et al.
Publicado: (2013)

The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates
por: Tomasicchio, Michele, et al.
Publicado: (2016)

What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
por: Sharma, Surendra K., et al.
Publicado: (2019)

GenoType(®) MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs
por: Theron, Grant, et al.
Publicado: (2016)

Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa
por: Oostvogels, Selien, et al.
Publicado: (2022)

Accelerate investment and action to find the missing patients with tuberculosis
por: Dheda, Keertan, et al.
Publicado: (2022)

Latent Tuberculosis Infection–associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?
por: Dheda, Keertan, et al.
Publicado: (2020)

Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
por: Metcalfe, John, et al.
Publicado: (2019)

The diagnostic accuracy of the GenoType® Mtbdrsl assay for the detection of resistance to second-line anti-tuberculosis drugs
por: Theron, Grant, et al.
Publicado: (2014)

The epidemiology of tuberculosis in health care workers in South Africa: a systematic review
por: Grobler, Liesl, et al.
Publicado: (2016)

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2017)

Drug resistance in intestinal tuberculosis: A reason to worry?
por: Sonambekar, Ajinkya, et al.
Publicado: (2017)

A Survey on Use of Rapid Tests and Tuberculosis Diagnostic Practices by Primary Health Care Providers in South Africa: Implications for the Development of New Point-of-Care Tests
por: Davids, Malika, et al.
Publicado: (2015)

Can Point-of-Care Urine LAM Strip Testing for Tuberculosis Add Value to Clinical Decision Making in Hospitalised HIV-Infected Persons?
por: Peter, Jonathan G., et al.
Publicado: (2013)

Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study
por: Kromer, Christian, et al.
Publicado: (2019)

Lung health in Africa: African solutions for African challenges – to infinity and beyond
por: Koegelenberg, Coenie, et al.
Publicado: (2018)

Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis
por: Dowdy, David W, et al.
Publicado: (2017)

Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?
por: Sabur, Natasha F., et al.
Publicado: (2017)

General characteristics and reasons for the discontinuation of drug clinical trials in mainland China
por: Huo, Ben-nian, et al.
Publicado: (2021)

Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa
por: Beynon, Fenella, et al.
Publicado: (2018)

The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report
por: Davids, Malika, et al.
Publicado: (2021)

Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa
por: Shah, N. Sarita, et al.
Publicado: (2011)

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2018)

Rationing tests for drug-resistant tuberculosis – who are we prepared to miss?
por: Martin, Laura J., et al.
Publicado: (2016)

Predictors of discordant latent tuberculosis infection test results amongst South African health care workers
por: Adams, Shahieda, et al.
Publicado: (2019)

Molecular epidemiology of drug resistant Mycobacterium tuberculosis in Africa: a systematic review
por: Chisompola, Namaunga Kasumu, et al.
Publicado: (2020)

Effects and determinants of tuberculosis drug stockouts in South Africa
por: Koomen, L. E. M., et al.
Publicado: (2019)

Distribution and Clonality of drug-resistant tuberculosis in South Africa
por: Said, Halima, et al.
Publicado: (2021)

Xpert(®) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
por: Kohli, Mikashmi, et al.
Publicado: (2018)

Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa
por: Klopper, Marisa, et al.
Publicado: (2013)

Reasons for Discontinuation or Change of Selective Serotonin Reuptake Inhibitors in Online Drug Reviews
por: Golder, Su, et al.
Publicado: (2023)

Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review
por: van Zyl-Smit, Richard N., et al.
Publicado: (2009)

Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting
por: Adams, Shahieda, et al.
Publicado: (2019)

Identification of Missing Carbon Fixation Enzymes as Potential Drug Targets in Mycobacterium Tuberculosis
por: Katiyar, Amit, et al.
Publicado: (2018)

Drug resistant tuberculosis in Africa: Current status, gaps and opportunities
por: Ismail, Nazir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5ie864psuqtbd6stj4opjncn2s